Integrin αL/ITGAL/CD11a Antibody (F-11): sc-373861

Integrin αL Antibody (F-11) is a mouse monoclonal IgG1 antibody that detects Integrin αL in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Integrin αL, also called CD11a, is a crucial component of the immune system, primarily expressed on leukocytes, where it plays a vital role in mediating cell adhesion and migration. Anti-Integrin αL antibody (F-11) recognizes a protein essential for immune response, as Integrin αL facilitates the interaction between leukocytes and the endothelium during inflammation, allowing immune cells to exit the bloodstream and reach sites of infection or injury. The structure of Integrin αL, which consists of a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail, enables conformational changes necessary for activation and function. These structural features allow Integrin αL to bind to ligands, such as intercellular adhesion molecules (ICAMs), effectively promoting cell-cell interactions critical for immune surveillance and response. Integrin αL monoclonal antibody (F-11) serves as an invaluable tool for researchers studying immune cell behavior, signaling pathways, and mechanisms underlying various inflammatory diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Integrin αL/ITGAL/CD11a Antibody (F-11) References:

1. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.  |  Bauer, RJ., et al. 1999. J Pharmacokinet Biopharm. 27: 397-420. PMID: 10826130
2. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.  |  Coffey, GP., et al. 2004. J Pharmacol Exp Ther. 310: 896-904. PMID: 15190122
3. Simvastatin regulates non-neuronal cholinergic activity in T lymphocytes via CD11a-mediated pathways.  |  Fujii, T., et al. 2006. J Neuroimmunol. 179: 101-7. PMID: 16828882
4. Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.  |  Johnson-Huang, LM., et al. 2012. PLoS One. 7: e30308. PMID: 22348003
5. The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells.  |  Karimzadeh, A., et al. 2018. Stem Cells Transl Med. 7: 468-476. PMID: 29543389
6. Systemic Delivery of Anti-Integrin αL Antibodies Reduces Early Macrophage Recruitment, Inflammation, and Scar Formation in Murine Burn Wounds.  |  Strudwick, XL., et al. 2020. Adv Wound Care (New Rochelle). 9: 637-648. PMID: 33124967
7. Cell adhesion molecules CD11a and CD18 in blood monocytes in old age and the consequences for immunological dysfunction. Preliminary results.  |  Chiricolo, M., et al. 1995. Gerontology. 41: 227-34. PMID: 7557500
8. Quantitative analysis of lymphocyte CD11a using standardized flow cytometry.  |  Pallis, M., et al. 1993. Scand J Immunol. 38: 559-64. PMID: 7902997
9. Hyperoxia induces platelet activation and lung sequestration: an event dependent on tumor necrosis factor-alpha and CD11a.  |  Barazzone, C., et al. 1996. Am J Respir Cell Mol Biol. 15: 107-14. PMID: 8679214
10. The neuronal glycoprotein telencephalin is a cellular ligand for the CD11a/CD18 leukocyte integrin.  |  Tian, L., et al. 1997. J Immunol. 158: 928-36. PMID: 8993013

The preferred Integrin αL/ITGAL/CD11a antibody is Integrin αL/ITGAL/CD11a Antibody (E-1): sc-374172.